DelAQUA Pharmaceuticals and Oxaphil GmbH Announce Strategic Collaboration
DelAQUA Pharmaceuticals and Oxaphil Announce Strategic Collaboration to Broaden the Use of Polyoxazolines for Advanced Drug Delivery Solutions
CHAPEL HILL, NC – February 6, 2026 – DelAQUA Pharmaceuticals (www.delaquapharma.com) today announced a strategic collaboration with Oxaphil GmbH (oxaphil.com) oxaphil.com) to utilize Oxaphil’s innovative and precise polyoxazoline (POx) synthesis expertise to advance DelAQUA’s polymer-based formulation approach to drug delivery. The partnership combines Oxaphil’s skill in providing complex and well-defined polymers with DelAQUA’s breakthrough solubility-enhancing technology to deliver next-generation drug delivery solutions to pharmaceutical and biotech partners worldwide.
DelAQUA’s polymeric micelle platform represents a significant advancement in addressing the challenges of formulating poorly soluble and unstable active pharmaceutical ingredients (APIs). The technology utilizes novel POx polymers at low concentrations to dramatically improve API solubility while maintaining the high drug loading attainable with POx polymers. By increasing solubility in this way, the complexity of parenteral and oral formulations is decreased to the benefit of the patient. This approach has shown promise in enhancing therapeutic efficacy and oral bioavailability while minimizing adverse side effects associated with the high excipient loads found in conventional delivery systems.
As DelAQUA sets its sights on drug delivery applications for a broad array of products, we immediately identified the Oxaphil team as the ideal development partner. They not only bring sparkling technical capabilities in polyoxazoline synthesis, they also have the agility and creativity necessary for successful outcomes for our more advanced drug delivery concepts in development. In addition, we think that this collaboration could act as an open invitation to the broader POx ecosystem to jointly address the challenges the industry will face in the coming years. – Bruce L. Frank, PhD, President and Chief Scientific Officer, DelAQUA Pharmaceuticals
The collaboration addresses a critical industry need for highly pure and well defined polyoxazolines for advanced formulation approaches that can improve the bioavailability, safety and stability of new drug products. By integrating Oxaphil’s ability to prepare complex but well-defined polymers with DelAQUA’s highly customizable and adaptive delivery platform, the partnership will enable accelerated development timelines for formulations precisely aligned with DelAQUA’s and their partners’ target product profiles.
“We are very pleased to further deepen our partnership with DelAQUA. Their formulation platform and application expertise perfectly complement Oxaphil’s capabilities as a manufacturer of highly defined POx materials. Together, we see significant potential to translate advanced polymer concepts into future-ready materials that can address real formulation challenges in drug delivery and help patients in the long run.” - Dr. Erik Wegener, CEO, Oxaphil
“POx materials have demonstrated their value in research for many years, but broad application requires the right partners and the right formulation context. Working closely with DelAQUA allows us to see these materials move from validated concepts into real pharmaceutical applications, where their structural versatility and performance can make a difference.” - Dr. Laura Fietzke, CSO, Oxaphil
About DelAQUA Pharmaceuticals, Inc.
DelAQUA Pharmaceuticals is a specialty pharmaceutical company headquartered in Chapel Hill, North Carolina, that has developed a breakthrough drug formulation platform utilizing advanced polymeric micelle technology. DelAQUA’s proprietary platform improves the solubility and stability of active pharmaceutical ingredients (APIs) by using novel polymers at low concentrations, effectively widening the therapeutic index of APIs while reducing formulation complexity. As demonstrated by DelAQUA’s collaborations with several multinational pharmaceutical companies, smaller pharmaceutical firms, and major research universities, the company’s technology has applications across multiple therapeutic areas. With the broad number of precise design properties available with this technology, novel drug formulations with improved therapeutic outcomes and additional intellectual property protection are on the horizon. The company is led by Bruce L. Frank, PhD, President and Chief Scientific Officer, a recognized expert in pharmaceutical drug product development and formulation science.
About Oxaphil GmbH
Oxaphil is a materials-focused deeptech company specializing in the scalable production of POx polymers, a highly modular polymer platform for advanced pharmaceutical formulations. Using proprietary high-throughput technologies, Oxaphil enables the industrial-scale manufacturing of POx with defined composition, purity and performance.POx materials are biocompatible, structurally tunable and well suited for solubility enhancement, drug delivery, and formulation stabilization. Oxaphil bridges the gap between academic innovation and real-world application by making research-proven POx materials reliably available for development and future GMP-relevant use.
